Bayer AG NA (BAYN) fair value: what the stock is really worth
We calculate from audited financials what Bayer AG NA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Bayer AG NA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 17, 2026.
How to read this chart
60‑month range €18.73 – €63.20 · fair‑value band €29.43 – €66.87 · the €49.03 price screens below the €49.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 17, 2026.
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments.
Show more
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Stock analysis
Bayer AG NA (BAYN) currently trades at €49.03, while our model-based Fair Value estimate is €49.36, implying the stock looks roughly 0.7% fairly valued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €95.79 per share, and 6 of the 15 models we run sit above the €49.03 price.
Bear case: the Growth DCF group reads lowest at €5.58, and 9 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: €29.43 (bear) to €66.87 (bull), the price of €49.03 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Bayer AG NA reported revenue of €45.6B in FY2025 versus €44.1B in FY2021, a compound +0.8%/yr. Reported net income was −€3.6B in FY2025.
Key figures
Market cap €48.2B · P/S ratio 1.03 · EPS (TTM) €−2.19 · Dividend yield 0.2% · Net margin −7.9% · Return on equity −6.9% · Return on assets (EBIT) 6.2% · Operating margin 26.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 1% below its 52-week high and 99% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 1%, BAYN screens cheaper than that median.
Fair Value models
Bear €29.43Fair Value €49.36Bull €66.87
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.0% (2020) → 15.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.0%
Yearly sales growth analysts expect, extended to five years.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 72 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Bottom 25%
Fair Value upside+8% · Above median
Profitability
Return on assets4% · Below median
Net margin (TTM)−5% · Bottom 25%
Operating margin (TTM)26% · Above median
Growth and dividend
Revenue growth−2% · Bottom 25%
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity1.19× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bayer AG NA Fair Value". https://www.fairvalue-calculator.com/stock/BAYN
Frequently asked questions
Is Bayer AG NA (BAYN) overvalued or undervalued?
As of Sep 17, 2026, our model estimates a fair value of €49.36 versus a price of €49.03, about +1% upside (fairly valued).
What is the fair value of BAYN?
Our model-based fair value for Bayer AG NA is €49.36 (as of Sep 17, 2026), built from audited fundamentals. The current price: €49.03.
What is the quality score of BAYN?
Bayer AG NA has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bayer AG NA (BAYN)?
Our model-based price target is the fair value of €49.36 (as of Sep 17, 2026) from 15 valuation models. Cautious scenario €29.43, optimistic scenario €66.87. It is a calculation from audited fundamentals, not an analyst target.
What is the Bayer AG NA stock forecast for 2026?
Our models put fair value at €49.36, about +1% upside versus a price of €49.03 (fairly valued). Cautious scenario €29.43, optimistic scenario €66.87. The calculation is refreshed regularly with new filings.
What is the revenue of Bayer AG NA (BAYN)?
Bayer AG NA reported trailing-twelve-month revenue of about €45.2B (latest available figure, as of Sep 17, 2026).
Does Bayer AG NA pay a dividend?
Bayer AG NA currently shows a dividend yield of about 0.22% relative to its recent price (as of Sep 17, 2026).
What growth is priced into Bayer AG NA (BAYN)?
For today's price to be fair in a discounted-cash-flow model, Bayer AG NA would have to grow free cash flow by +17.2 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.9 % per year. As of Sep 17, 2026.
What discount rate (WACC) does the fair value of BAYN use?
Our models discount Bayer AG NA at 8.6 %: a base by market capitalisation (large), damped by beta 0.83, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bayer AG NA that is +17.2 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Bayer AG NA (BAYN) delivered so far?
Over the past 5 years revenue at Bayer AG NA grew +1.9 % a year. The price currently implies +17.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bayer AG NA (BAYN) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Bayer AG NA (+17.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bayer AG NA (BAYN)?
The free-cash-flow yield on the price is 4.41 %: that much free cash flow Bayer AG NA produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bayer AG NA (BAYN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bayer AG NA it is €49.36 per share (as of Sep 17, 2026), against a price of €49.03. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Bayer AG NA stock overvalued or undervalued in 2026?
As of Sep 17, 2026, BAYN trades below its calculated fair value: price €49.03, fair value €49.36, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BAYN?
No. The price is what the market pays today (€49.03); the fair value is what the company's own numbers justify (€49.36). For Bayer AG NA the two are €0.3300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bayer AG NA worth?
The market values Bayer AG NA at about €48.2B (market capitalisation, as of Sep 17, 2026). Per share that is €49.03; our models calculate a fair value of €49.36 per share.
What do the bullish and bearish scenarios say about BAYN?
Our models span a range for Bayer AG NA: cautious scenario €29.43, base €49.36, optimistic €66.87 per share (as of Sep 17, 2026, price €49.03). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BAYN?
The PEG ratio of Bayer AG NA is 4.72 (P/E divided by earnings growth, as of Sep 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bayer AG NA (BAYN)?
Balance-sheet figures for Bayer AG NA (as of Sep 17, 2026): return on equity −6.9%, debt of 1.19 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is BAYN from its 52-week high?
Bayer AG NA trades at €49.03, about 1% below its 52-week high of €49.64 and 99% above the low of €24.60 (as of Sep 17, 2026). Distance from the high says nothing about value: that is what the fair value of €49.36 is for.
Which stocks are comparable to Bayer AG NA?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bayer AG NA stock attractive at the current price?
The data as of Sep 17, 2026: price €49.03, calculated fair value €49.36 (+1%), Quality Score 46/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BAYN calculated?
We run Bayer AG NA through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €49.36, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Bayer AG NA currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bayer AG NA (BAYN)?
The closing price on Sep 21, 2026 was €49.03. Our model-based fair value is €49.36, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bayer AG NA right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (€29.43 to €66.87) leaves room in how you read the outcome.
Key figures of Bayer AG NA
How large is the market capitalisation of Bayer AG NA (BAYN)?
The market capitalisation of Bayer AG NA is €48.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bayer AG NA (BAYN)?
The price-to-sales ratio of Bayer AG NA is 1.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bayer AG NA (BAYN)?
Earnings per share at Bayer AG NA are €−2.19. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bayer AG NA (BAYN)?
The dividend yield of Bayer AG NA is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bayer AG NA (BAYN)?
The net margin of Bayer AG NA is −7.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bayer AG NA (BAYN)?
The return on equity (ROE) of Bayer AG NA is −6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bayer AG NA (BAYN)?
On an EBIT basis the return on assets of Bayer AG NA is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bayer AG NA (BAYN)?
The operating margin of Bayer AG NA is 26.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bayer AG NA (BAYN)?
Revenue at Bayer AG NA is growing −2.4% versus a year earlier (3y avg −3.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bayer AG NA (BAYN)?
Earnings per share at Bayer AG NA are growing +113% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bayer AG NA (BAYN) carry?
The net debt of Bayer AG NA is €30.8B (fiscal year 2025, ≈ 14.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bayer AG NA in the live analysis
One click puts Bayer AG NA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 17, 2026